The New England Journal of Medicine
e-mail icon  FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |    Advanced Search
Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe
 
Correspondence
PreviousPrevious
Volume 357:1982-1984 November 8, 2007 Number 19
NextNext

11C-Labeled Methionine and Evaluation of Malignant Pleural Mesothelioma

Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

 Sign up for free e-toc
 

This Article
-Full Text
- PDF
-PDA Full Text
-Purchase this article

Tools and Services
-Add to Personal Archive
-Add to Citation Manager
-Notify a Friend
-E-mail When Cited
-E-mail When Letters Appear

More Information
-PubMed Citation
To the Editor: Assessing responses to treatment on the basis of computed tomographic (CT) measurements in patients with malignant pleural mesothelioma is challenging because of the pattern of growth of this disease.1 There is evidence that 18F-fluorodeoxyglucose positron-emission tomography (FDG-PET) can detect the response of a tumor to chemotherapy or chemoradiotherapy early in the course of treatment.2 A few pilot studies have explored the role of FDG-PET in patients with malignant pleural mesothelioma who were treated with chemotherapy, with promising results.3 Nevertheless, the usefulness of FDG is limited by its uptake in inflammatory cells such as macrophages and activated lymphocytes, . . . [Full Text of this Article]



HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  HELP  |  beta.nejm.org

Comments and questions? Please contact us.

The New England Journal of Medicine is owned, published, and copyrighted © 2008 Massachusetts Medical Society. All rights reserved.